Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7811435 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL8311603 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL9486743 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL4523110 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL7811433 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL1686983 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL22582139 | 0.96 | USP2 (0.31) | USP2ESR1KDM4E | |
| SCHEMBL16673765 | 0.77 | — | — | |
| SCHEMBL19486294 | 0.74 | — | — | |
| SCHEMBL9470709 | 0.74 | USP2 (0.37) | USP2ESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3978472-B1 | BIARYL MONABACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-108368040-B | Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-3978472-A1 | BIARYL MONABACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3390357-B1 | BIARYL MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2020-11-19 | — | — | US | disclosed |
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| EP-3390357-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | Merck Sharp & Dohme Corp. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9782390-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9782390-B2 | Amidine substituted β-lactam compounds, their preparation and use as antibacterial agents | AICURIS GMBH & CO. KG (DE) | 2017-10-10 | — | — | US | disclosed |
| EP-0342423-A2 | Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics | E.R. SQUIBB & SONS, INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| US-4775670-A | BACTERICIDES, ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0048953-B1 | BETA-LACTAM ANTIBIOTICS | E.R. Squibb & Sons, Inc. (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4652651-A | Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid intermediates via catalytic ester cleavage | HOFFMANN-LA ROCHE INC. (US) | 1987-03-24 | — | — | US | disclosed |
| US-4625022-A | Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts | E. R. SQUIBB & SONS, INC. (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0187355-A1 | Process for preparing beta-lactam antibiotics | E.R. Squibb & Sons, Inc. (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4529698-A | Culturing Chromobacterium | E. R. SQUIBB & SONS, INC. (US) | 1985-07-16 | — | — | US | disclosed |
| EP-0096297-A2 | Process for the preparation of 1-sulfo-2-oxoazetidine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-12-21 | — | — | EP | disclosed |
| US-4386034-A | Sulfamated amino acid amides | E. R. SQUIBB & SONS, INC. (US) | 1983-05-31 | — | — | US | disclosed |
| EP-0048953-A2 | Beta-lactam antibiotics | E.R. Squibb & Sons, Inc. (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339983-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | BMX, BTK, ABCB11 | FAP 2957/4885USP2 3912/4885ESR1 4314/4885 |
| US-11230543-B2 | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | SQLE, ABCB11, BMX | FAP 3031/4885USP2 3181/4885ESR1 4204/4885 |
| US-20200361928-A1 | BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | ABCB11, SQLE, BMX | FAP 3139/4885USP2 3279/4885ESR1 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.